Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8146 to 8160 of 9042 results

  1. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    Discontinued Reference number: GID-TA11265

    Technology appraisal guidance
    Discontinued

  2. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    In development Reference number: GID-TA11645 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  5. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  7. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    In development Reference number: GID-TA11008 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued Reference number: GID-TA11034

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued Reference number: GID-TA11024

    Technology appraisal guidance
    Discontinued

  10. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

    Technology appraisal guidance
    Discontinued

  11. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued Reference number: GID-TA11180

    Technology appraisal guidance
    Discontinued

  13. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

    Technology appraisal guidance
    Discontinued

  14. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    Discontinued Reference number: GID-TA11253

    Technology appraisal guidance
    Discontinued

  15. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    Discontinued Reference number: GID-TA11302

    Technology appraisal guidance
    Discontinued